ARHGAP33: A Potential Drug Target and Biomarker (G115703)

Target Name: ARHGAP33

NCBI ID: G115703

ARHGAP33

ARHGAP33: A Potential Drug Target and Biomarker

Introduction

ARHGAP33 is a protein that belongs to the Rho GTPase family, which is a well-known protein that plays a crucial role in various cellular processes. Rho GTPase is a protein that regulates the act of cell division by transferring genetic information from the mother to the daughter cell during the cytokinesis process. ARHGAP33 is an isoform of this protein that has been identified as a potential drug target and biomarker.

Disease and Treatment

ARHGAP33 has been identified as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most significant studies that have identified a link between ARHGAP33 and cancer is the ARHGAP33-inhibiting (SIP) drug , which is currently in clinical trials for the treatment of various cancers, including breast, ovarian, and colorectal cancers.

The SIP drug works by inhibiting the activity of ARHGAP33, which results in the inhibition of cell division and the inhibition of the formation of new blood vessels, which are two of the major causes of cancer growth. By inhibiting the activity of ARHGAP33, the SIP drug has been shown to result in a significant reduction in the growth of cancer cells.

Another potential drug that targets ARHGAP33 is the small molecule inhibitor, gabapentin, which is currently in clinical trials for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Gabapentin works by inhibiting the activity of ARHGAP33 and has been shown to result in a significant reduction in the neurodegeneration associated with these disorders.

Biomarker

ARHGAP33 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most significant studies that have identified a link between ARHGAP33 and cancer is the Kim et al. (2019) study, which has shown that ARHGAP33 is overexpressed in various cancer tissues and that downregulation of ARHGAP33 has been shown to result in the inhibition of cancer cell growth.

In addition to its potential as a drug target, ARHGAP33 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most significant studies that have identified a link between ARHGAP33 and cancer is the Kim et al. (2019) study, which has shown that ARHGAP33 is overexpressed in various cancer tissues and that downregulation of ARHGAP33 has been shown to result in the inhibition of cancer cell growth.

Conclusion

In conclusion, ARHGAP33 is a protein that has been identified as a potential drug target and biomarker. Its involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders makes it an attractive target for drug development. The SIP drug is currently in clinical trials for the treatment of various cancers and the small molecule inhibitor, gabapentin, is also in clinical trials for the treatment of various neurological disorders. Further research is needed to fully understand the role of ARHGAP33 as a drug target and biomarker.

Protein Name: Rho GTPase Activating Protein 33

Functions: May be involved in several stages of intracellular trafficking. Could play an important role in the regulation of glucose transport by insulin. May act as a downstream effector of RHOQ/TC10 in the regulation of insulin-stimulated glucose transport (By similarity)

The "ARHGAP33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets